BR112022014563A2 - Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose i (mps i) - Google Patents
Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose i (mps i)Info
- Publication number
- BR112022014563A2 BR112022014563A2 BR112022014563A BR112022014563A BR112022014563A2 BR 112022014563 A2 BR112022014563 A2 BR 112022014563A2 BR 112022014563 A BR112022014563 A BR 112022014563A BR 112022014563 A BR112022014563 A BR 112022014563A BR 112022014563 A2 BR112022014563 A2 BR 112022014563A2
- Authority
- BR
- Brazil
- Prior art keywords
- mucopolysaccharidosis
- mps
- human subject
- subject diagnosed
- treatment
- Prior art date
Links
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 title abstract 3
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 102100035028 Alpha-L-iduronidase Human genes 0.000 abstract 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 1
- 102000056929 human IDUA Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
MÉTODO PARA TRATAMENTO DE UM SUJEITO HUMANO DIAGNOSTICADO COM MUCOPOLISSACARIDOSE I (MPS I). Composições e métodos são descritos para a distribuição de uma a-L-iduronidase (IDUA) totalmente humana e glicosilada (HuGly) ao líquido cefalorraquidiano do sistema nervoso central (SNC) de um sujeito humano diagnosticado com mucopolissacaridose I (MPS I).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062964351P | 2020-01-22 | 2020-01-22 | |
US202063086145P | 2020-10-01 | 2020-10-01 | |
PCT/US2021/014129 WO2021150570A1 (en) | 2020-01-22 | 2021-01-20 | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022014563A2 true BR112022014563A2 (pt) | 2022-09-13 |
Family
ID=74592808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022014563A BR112022014563A2 (pt) | 2020-01-22 | 2021-01-20 | Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose i (mps i) |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230059395A1 (pt) |
EP (1) | EP4093428A1 (pt) |
JP (1) | JP2023511382A (pt) |
KR (1) | KR20220131522A (pt) |
AU (1) | AU2021211416A1 (pt) |
BR (1) | BR112022014563A2 (pt) |
CA (1) | CA3167685A1 (pt) |
IL (1) | IL294625A (pt) |
WO (1) | WO2021150570A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018298133A1 (en) | 2017-07-06 | 2020-01-23 | The Trustees Of The University Of Pennsylvania | AAV9-mediated gene therapy for treating mucopolysaccharidosis type I |
US11819539B2 (en) | 2017-09-22 | 2023-11-21 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating Mucopolysaccharidosis type II |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU781958C (en) | 1999-08-09 | 2006-03-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
ES2648241T3 (es) | 2003-09-30 | 2017-12-29 | The Trustees Of The University Of Pennsylvania | Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos |
ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
WO2012057363A1 (ja) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
US9409953B2 (en) | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
PL3254703T3 (pl) | 2011-04-22 | 2020-10-05 | The Regents Of The University Of California | Wiriony wirusa towarzyszącego adenowirusom z różnymi kapsydami i sposoby ich zastosowania |
EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
JP6385920B2 (ja) | 2012-05-09 | 2018-09-05 | オレゴン ヘルス アンド サイエンス ユニバーシティー | アデノ随伴ウイルスプラスミド及びベクター |
AU2014244167A1 (en) | 2013-03-13 | 2015-10-08 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
WO2015038958A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
CA3012195A1 (en) * | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
EP3541946A1 (en) * | 2016-11-15 | 2019-09-25 | Regents Of The University Of Minnesota | Method for improving neurological function in mpsi and mpsii and other neurological disorders |
JP2020508289A (ja) * | 2017-01-31 | 2020-03-19 | レジェンクスバイオ インコーポレーテッド | 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療 |
AU2018298133A1 (en) * | 2017-07-06 | 2020-01-23 | The Trustees Of The University Of Pennsylvania | AAV9-mediated gene therapy for treating mucopolysaccharidosis type I |
-
2021
- 2021-01-20 BR BR112022014563A patent/BR112022014563A2/pt not_active Application Discontinuation
- 2021-01-20 CA CA3167685A patent/CA3167685A1/en active Pending
- 2021-01-20 WO PCT/US2021/014129 patent/WO2021150570A1/en unknown
- 2021-01-20 IL IL294625A patent/IL294625A/en unknown
- 2021-01-20 EP EP21705055.8A patent/EP4093428A1/en active Pending
- 2021-01-20 AU AU2021211416A patent/AU2021211416A1/en active Pending
- 2021-01-20 US US17/792,960 patent/US20230059395A1/en active Pending
- 2021-01-20 KR KR1020227025630A patent/KR20220131522A/ko active Search and Examination
- 2021-01-20 JP JP2022544318A patent/JP2023511382A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL294625A (en) | 2022-09-01 |
KR20220131522A (ko) | 2022-09-28 |
CA3167685A1 (en) | 2021-07-29 |
US20230059395A1 (en) | 2023-02-23 |
WO2021150570A1 (en) | 2021-07-29 |
AU2021211416A1 (en) | 2022-08-11 |
JP2023511382A (ja) | 2023-03-17 |
EP4093428A1 (en) | 2022-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022014563A2 (pt) | Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose i (mps i) | |
UY37587A (es) | Tratamiento de mucopolisacaridosis i con alfa-l-iduronidasa (idua) humana glicosilada completamente humana | |
BR112018074979A2 (pt) | composições de limpeza que compreendem enzimas | |
BR112022015183A2 (pt) | Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii) | |
NZ743008A (en) | Compositions and methods for internalizing enzymes | |
BR112019023169A2 (pt) | Método e aparelho para sinalização de informações de sistema | |
BR102016004084A8 (pt) | Sistema para testar juntas isoladas em um sistema de via e módulo de teste | |
BR112018014118A2 (pt) | sistema e processo de medida de uma propriedade de escoamento de um fluido no seio de um meio poroso | |
BR112017008482A2 (pt) | métodos e sistema para suprimir a corrosão das superfícies de aço | |
BR112018070189A2 (pt) | método para seleção de proteínas recombinantes ricas em m6p | |
BR112017007155A2 (pt) | líquidos iônicos comutáveis para pré-tratamento da biomassa e hidrólise enzimática | |
BR112018016971A2 (pt) | aparelho, sistema e método de inspeção de formato de eixo de manivela | |
MX2019006421A (es) | Composiciones de limpieza que incluyen enzimas. | |
MX2018000588A (es) | Uso de amitriptilina para el bloqueo de hemicanales en el cerebro y metodo para la potenciacion de este efecto in vivo. | |
BR112021026866A2 (pt) | Composições de vetor e métodos de seu uso para o tratamento de distúrbios do armazenamento lisossômico | |
BR112018068721A2 (pt) | método para contar células e aparelho | |
AR121083A1 (es) | TRATAMIENTO DE MUCOPOLISACARIDOSIS I CON a-L-IDURONIDASA (IDUA) HUMANA GLICOSILADA COMPLETAMENTE HUMANA | |
BR112023016075A2 (pt) | Método para tratar hepatoesplenomegalia, método de distribuição de um raav que codifica hids, método para tratar um sujeito humano, método de tratamento de um sujeito humano, método para determinar a eficácia do tratamento, método para identificar um sujeito como tendo mps ii | |
BR112017015782A2 (pt) | combinação de duas ou mais enzimas de lípase, preparação farmacêutica, uso de uma combinação de duas ou mais enzimas de lípase, método para a produção de uma combinação de duas ou mais enzimas de lípases e duas ou mais moléculas de ácido nucléico | |
AR121200A1 (es) | Tratamiento de la mucopolisacaridosis tipo ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas | |
Farhadi et al. | The Effectiveness of Dialectical Behavior Therapy in Reducing Expulsive Anger | |
BR112017022519A2 (pt) | método para injetar e detectar uma composição em um sistema de fluido de perfuração, sistema para injetar e detectar gás e aparelho para injetar e detectar | |
WO2021108667A3 (en) | Methods of reducing biuret in urea compositions | |
BR112022009085A2 (pt) | Sistemas disruptivos de acoplamento e métodos para sistemas submarinos | |
AR096039A1 (es) | Un método para el desgomado enzimático acuoso de aceites vegetales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |